Home › Trials › NCT04328298

Registry of patients eligible for CAR-T cell treatment in France

French Register Of Patients With Hemopathy Eligible For CAR-T Cell Treatment (DESCAR-T)

Observational The Lymphoma Academic Research Organisation · NCT04328298

This study is gathering information about patients with blood cancers who are considered for CAR-T cell treatment in France to see how well the therapy works for them.

Quick facts

Study typeObservational
Enrollment5000 (estimated)
Ages0 Years to 99 Years
SexAll
SponsorThe Lymphoma Academic Research Organisation Academic / other
Drugs / interventionsCAR-T
Locations36 sites (Amiens and 35 other locations)
Trial IDNCT04328298 on ClinicalTrials.gov

What this trial studies

This registry collects both prospective and retrospective data on patients who have been evaluated for CAR-T cell treatment in multidisciplinary tumor boards. It aims to document the eligibility and outcomes of patients with hematological malignancies who are treated with CAR-T therapy. The registry includes patients treated since July 2018 under temporary authorization or covered by the French health insurance system. Data collection is conducted with patient consent, ensuring ethical standards are maintained.

Who should consider this trial

Good fit: Ideal candidates include patients with hematological malignancies who have been deemed eligible for CAR-T cell treatment by a multidisciplinary tumor board.

Not a fit: Patients with non-hematological malignancies or those not eligible for CAR-T cell treatment will not benefit from this registry.

Why it matters

Potential benefit: If successful, this registry could improve understanding of CAR-T cell treatment outcomes and enhance patient selection for future therapies.

How similar studies have performed: Other registries and studies have shown success in documenting CAR-T treatment outcomes, indicating that this approach is supported by prior evidence.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

Retrospective inclusion :

* Patient treated with CAR-T from 1 July 2018 under temporary authorization (ATU) or covered by French health insurance system (under post-ATU or MA) in a qualified center before activation of this register in this center
* If the patient is alive, the patient has been informed of the collection and use of their data, and the patient has not opposed this use. If the patient has died, the patient did not opposed the use of their data while alive

Prospective inclusion :

* Patient eligible for a treatment with CAR-T for an hematological malignancy which is covered by French health insurance (for ATUs / post-ATUs or MA), or as part of a clinical trial with the same indication, after the activation of this register in this center.
* Patient whose CAR-T indication has been validated during a multidisciplinary tumor board (RCP) of a qualified center, according to the ministerial order of 8 August 2019
* Patient deemed eligible for a treatment with CAR-T after a medical exam performed in a qualified center according to the ministerial order of 8 August 2019
* If the patient is alive, the patient has been informed of the collection and use of their data, and the patient has not opposed this use. If the patient has died, the patient did not opposed the use of their data while alive.

Exclusion Criteria Patient not registered with the social security in France

Where this trial is running

Amiens and 35 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Hematopathology Eligible or CAR-t Cell Treatment
Last reviewed 2026-06-10 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.